TRUE

Truetide PLC

Financial Services First-pass screen £1.33m

320/1000 Overall fit

AI beneficiary 35% 35

Operating leverage 25% 32

Valuation 25% 32

Downside protection 15% 25

First-pass take

Cash-burning AIM holding company with modest AI exposure via Imaging Biometrics' brain tumor imaging software (29.5% stake, Phase 1 clinical trial). Portfolio spans early-stage biotech and industrial tech with limited commercialization. Trading 35% premium to NAV; £64k cash against £1.7m annual burn creates precarious capital structure.

Flags

loss-makingcash-burnmicro-capilliquid-portfoliogoing-concern-risk